Agreed. I assume covid restrictions and subsequent issues with the hospital system have impacted clinical trials. I am really surprised we haven’t received a “first patient treated” announcement for the DFU trial, as this is a condition that is genuinely not elective.
Not holding my breath, however some comments from Ross in the quarterly about how the current environment is impacting the trials would be well received by the market.
Issues with communication aside, I just can’t see how Cynata is at this market cap with the following known catalysts:
ARDS enrolment complete + results (Q1)
DFU 1st patient enrolled (Q1)
GVHD IND, trial structure and start (Q1 + Q2)
IPF Samuels pre-clinical dosing data (Q1 or Q2)
Agreed. I assume covid restrictions and subsequent issues with...
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.010(4.26%) |
Mkt cap ! $40.41M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 22.5¢ | $11.57K | 49.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 100000 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 7426 | 1 |
View Market Depth
| Last trade - 15.43pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
23.0¢ |
Change
-0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 23.0¢ | 23.5¢ | 23.0¢ | 10710 | ||
| Last updated 15.01pm 10/05/2024 ? | |||||
| CYP (ASX) Chart |